Treats Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 78690, held by Sun Pharm. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 78690 (Carbidopa And Levodopa), held by Sun Pharm, was first approved by FDA on Jul 31, 2009, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson’s disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa orally disintegrating tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 2009 | Original application | Approved | None posted |
| Carbidopa And Levodopa10MG;100MG · tablet, orally disintegrating;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;100MG · tablet, orally disintegrating;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;250MG · tablet, orally disintegrating;oral | Carbidopa; Levodopa | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters